MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Splenic Marginal Zone Lymphoma Clinical Trial

— MALIBU  

Official title:

MALIBU Trial - Phase II Study of Combination Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03697512
• Other study ID #: IELSG47
• Secondary ID: 2018-002364-44
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: September 27, 2019
• Est. completion date: June 15, 2027

Study information

• Verified date: May 2023
• Source: International Extranodal Lymphoma Study Group (IELSG)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Single-arm, phase II clinical trial of patients with Extranodal Marginal Zone Lymphoma (EMZL). It is planned to recruit 130 patients. Additional patients with Splenic Marginal Zone Lymphoma (SMZL), up to 30, and Nodal Marginal Zone Lymphoma (NMZL), up to 15, will be included in the trial in order to preliminary explore the clinical activity and safety of the combination treatment proposed. The study primary endpoints will be analysed on the EMZL population. Outcome of patients with SMZL and NMZL will be analysed and reported separately

Description:

Marginal zone lymphomas (MZL) represent a group of indolent B-cell lymphomas that arises from marginal zone B-cells in extranodal tissues, such as spleen and mucosa associated lymphoid tissues, and more rarely also in nodal tissues. MZL comprises 5 to 17% of all non-Hodgkin lymphomas (NHL) in adults. The 2016 World Health Organization (WHO) recognized three separate subtypes of MZL according to their primary localization, namely the: 1. extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT), also known as MALT lymphoma 2. splenic MZL (SMZL) 3. nodal MZL (NMZL). These three subtypes are distinct disease entities that are classified together because they all seem to originate from post germinal centre marginal zone B-cells. MALIBU trial is a prospective multicenter trial combining rituximab and ibrutinib in front-line for patients with MZL, including EMZL, SMZL and NMZL Aim of the study is to assess the safety and efficacy of the combination of rituximab and ibrutinib in EMZL patients and to explore its activity in SMZL and NMZL as exploratory subset.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 175
• Est. completion date: June 15, 2027
• Est. primary completion date: June 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Chemotherapy and immunotherapy-naïve, symptomatic and in need of treatment patients, with

histologically proven CD20-positive MZL, not eligible for local therapy, including:

1. EMZL (MALT Lymphoma) patients with MALT- IPI score 1-2 in need of systemic therapy. Either de novo or relapsed following local therapy (including surgery, radiotherapy and antibiotics for H. pylori-positive gastric lymphoma) arisen at any extranodal site with MALT-international prognostic index (IPI) score 1-2 at the time of study entry.

1.1.The following patients with gastric MALT Lymphoma can be entered:

1. H. pylori-negative cases, either de novo (non pretreated) or at relapse following local therapy (i.e., surgery, radiotherapy or antibiotics).

2. H. pylori-positive cases at diagnosis, who either first line antibiotics or

further local treatment (surgery or radiotherapy), including patients with:

• clinical (endoscopic) and histological evidence of disease progression at any time post H. pylori eradication;
• clinical (endoscopic) and histological relapse (without H. pylori re-infection), after a remission patients;
• persistent (stable) lymphoma at = 1 year post H. pylori eradication. 1.2. Similar consideration may be applied to patients with ocular adnexal lymphoma treated with antibiotics.

2. SMZL patients in need of therapy. Either de novo or relapsed following local therapy [including surgery and antiviral therapy for Hepatitis C virus (HCV)]. Patient must have a symptomatic disease requiring treatment and be not eligible for splenectomy or not willing to undergo splenectomy.

2.1. Patients with SMZL can be entered if any of the following criteria is present:

1. bulky progressive or painful splenomegaly;

2. enlarged lymph nodes or involvement of extranodal sites with or without cytopenias , i.e. involvement of =3 nodal sites, each with a diameter of =3 cm. Any nodal tumor mass with a diameter of =7 cm (GELG criteria, as adopted in follicular lymphoma);

3. one of the following symptomatic/progressive cytopenias:

• Hgb < 10 g/dL;
• ANC < 1000/µL:
• PLT< 80 000/µL whatever the reason (autoimmune or hypersplenism or bone marrow infiltration). 2.2. Splenectomised patients with rapidly raising lymphocyte counts, lymphadenopathy or involvement of extranodal sites can be entered. 2.3. SMZL with concomitant HCV infection who have not responded to or are relapsed after antiviral therapy can be entered.

3. NMZL patients in need of therapy Either, de novo presenting with disseminated disease or relapsed after local radiotherapy or following antiviral therapy for HCV. Localized nodal MZL is not eligible.

• Measurable or evaluable disease.
• Ann Arbor II-IV. Stage I disease may be eligible only if not candidate to local therapy (surgery or radiotherapy).
• Age = 18.
• Life expectancy of at least 1 year.
• ECOG Performance status 0-2.
• Adequate bone marrow, kidney and liver function
• For women of childbearing potential only: negative serum pregnancy test done within 7 days prior to study drugs administration or within 14 days if with a confirmatory urine pregnancy test within 7 days prior to the first study drugs administration.
• Fertile male or female patients of childbearing potential and their partners must use higly effective contraception methods during the study and for at least 12 months after the last dose of subcutaneous rituximab. In case hormonal methods of birth control is used a barrier method must be added.
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

1. Any type of lymphoma other than MZL (including MZL with histologic transformation to high-grade lymphoma).

2. Localized (stage IE and IIE) MALT lymphoma, for example gastric, ocular and cutaneous lymphoma, that may benefit from local therapy only (surgery or radiotherapy).

3. Known CNS involvement of MZL.

4. Any previous systemic treatment with immunotherapy or chemotherapy or with BTK inhibitors.

5. Major surgery within 4 weeks prior to registration.

6. History of stroke or intracranial bleeding within 6 months.

7. Known bleeding diathesis (eg, von Willebrand's disease) or hemophilia.

8. Concurrent use of warfarin of other vitamin K antagonists.

9. Concurrent use of strong cytochrome P450 (CYP)3A4/5 inhibitors (see http://medicine.iupui.edu/clinpharm/ddis/clinical-table/).

10. Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk.

11. International normalized ratio (INR) or prothrombin time (PT) =1.5 ULN. Partial thromboplastin time (PTT) or activated PTT (aPTT) =1.5 ULN unless due to lupus anticoagulant.

12. Vaccinated with live, attenuated vaccines within 4 weeks prior to randomization.

13. Clinically significant hypersensitivity (e.g., anaphylactic or anaphylactoid reactions to the compound of ibrutinib and/or rituximab themselves or to the excipients in their formulation).

14. Positive test results for chronic HBV infection (defined as positive HBsAg serology).

15. Patients with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) may be included if HBV DNA is undetectable, provided that they are willing to undergo monthly DNA testing and taking specific antiviral prophylaxis, according to local policy. Patients who have protective titers of hepatitis B surface antibody (HBsAb) after vaccination are eligible.

16. Positive test results for hepatitis C. Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA.

17. HIV infection or immunodeficiency.

18. Active, severe infections

19. Pregnancy or breastfeeding.

20. Clinically significant cardiovascular diseases such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification.

21. Any serious medical or psychiatric illness likely to interfere with participation in this clinical study.

22. Prior history of malignancies other than MZL within 3 years,with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer.

23. Current enrolment or participation in another therapeutic clinical trial within 28 days prior to treatment start

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell, Marginal Zone
• Marginal Zone Lymphoma
• Nodal Marginal Zone Lymphoma
• Splenic Marginal Zone Lymphoma

Intervention

Drug:
• Ibrutinib
capsules for oral intake in a dosage of 560 mg (four capsules) daily
• Rituximab
Concentrate solution for infusion - intravenous use; Solution for injection - subcutaneous use.

Locations

Country	Name	City	State
Belgium	CHU UCL Namur / site Godinne	Yvoir
France	Institut Bergonié	Bordeaux
France	IHBN - CHU Côte de Nacre	Caen
France	CHU d'Estaing	Clermont-Ferrand	Cedex 1
France	CHU Dijon Bourgogne - Hôpital François Mitterand	Dijon
France	CHU de Grenoble - Hôpital Albert MICHALLON	La Tronche
France	CHU de Montpellier	Montpellier	Cedex 05
France	Saint Louis Hospital	Paris
France	Centre Hospitalier Lyon Sud	PIERRE-BENITE Cedex
France	CHU de Rennes Pontchaillou	Rennes	Cedex 9
France	CHRU de Strasbourg	Strasbourg
France	IUCT Oncopole Toulouse	Toulouse
France	CHU de Tours - Hôpital Bretonneau	Tours	Cedex 01
France	CHU de Nancy - Hôpital Brabois	Vandœuvre-lès-Nancy
Italy	Azienda Ospedaliera Universitaria Ospedali Riuniti - Università Politecnica delle Marche	Ancona
Italy	IRCCS Centro di Riferimento Oncologico di Aviano	Aviano	PN
Italy	Giovanni Paolo II/I.R.C.C.S. Istituto Tumori	Bari
Italy	A.O. Spedali Civili di Brescia	Brescia
Italy	Ospedale Oncologico Businco	Cagliari
Italy	AAST Grande Ospedale Metropolitano Niguarda	Milano
Italy	Fondazione IRCCS - Cà Granda - Ospedale Maggiore Policlinico	Milano
Italy	Fondazione IRCCS - Istituto Nazionale dei Tumori	Milano
Italy	Ospedale San Raffaele	Milano	MI
Italy	Fondazione IRCCS - Policlinico San Matteo	Pavia
Italy	Ospedale degli Infermi	Ponderano	BI
Italy	U.O. Ematologia AUSL Ravenna	Ravenna
Italy	Azienda Ospedaliera Arcispedale Santa Maria Nuova IRCCS	Reggio Emilia
Italy	Università degli Studi di Roma La Sapienza	Roma
Italy	A.O.U. Città della Salute e della Scienza di Torino Ospedale Molinette	Torino	TO
Italy	Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI)	Trieste
Italy	Ospedale di Circolo e Fondazione Macchi di Varese	Varese
Portugal	Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E.	Lisboa
Switzerland	Kantonalspital Baden	Baden
Switzerland	Istituto Oncologico della Svizzera Italiana (IOSI)	Bellinzona	TI
Switzerland	Inselspital Bern	Bern
Switzerland	Hôpitaux Universitaires de Genève	Genève
Switzerland	Universitätsspital Zürich	Zürich

Sponsors (1)

Lead Sponsor	Collaborator
International Extranodal Lymphoma Study Group (IELSG)

Countries where clinical trial is conducted

Belgium,  France,  Italy,  Portugal,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete Response Rate at 12 months	The proportion of patients with complete response after 12 months from treatment start	12 months after treatment start
Primary	Progression Free Survival at 5 years	The proportion of patients without disease progression after 5 years from treatment start	5 years from treatment start
Secondary	Number of treatment-Emerging Adverse Events	Analysis of incidence, severity and relationship of adverse events graded according to NCI Common Toxicity Criteria, version 4.0	From the time of informed consent signature until 28 days after treatment discontinuation or until resolution of all treatment-related AEs, whichever occurs later
Secondary	Complete Response Rate at 24 months	The proportion of patients with complete response after 24 months from treatment start	24 months from treatment start
Secondary	Overall Response Rate at 12 and 24 months	The proportion of responding patients (partial and complete responses) assessed at 12 and 24 months after treatment start	12 and 24 months after treatment start
Secondary	Overall survival	The time from the date of treatment start to the date of death from any cause	From the date of treatment start to the date of death due to any cause until 5 years from treatment discontinuation